Board of Directors
Eugen Steiner
Born: 1954
Other assignments: Chairman of the board of Empros Pharma AB. Board member of Inbox Capital AB and Stockholm School of Entrepreneurship. Member of Royal Swedish Academy of Engineering (IVA) and deputy chairman of its Division X, Biotechnology.
Education: Karolinska Institutet (M.D., Ph.D. in Clinical Pharmacology).
Experience and prior assignments: CEO or acting chairman of the board in several life science companies in Sweden, Norway, Iceland, the UK and the US for more than 35 years.
Board member since: 2017 (Chairman of the Board since 2023)
Committee membership: Remuneration Committee
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 89,000 Class B shares
Cecilia Edström
Born: 1966
Other assignments: Founder and CEO, ceed konsult AB. Board member of Flerie AB and A3P Biomedical AB. Advisory Board Member, European Patient Safety Foundation (EUPSF). Chairman of the board of Perspetivo AB.
Education: Master of Business Administration, Stockholm School of Economics, Sweden.
Experience and prior assignments: More than 30 years of experience in various industries, including life science. Executive roles including CEO and CFO at Bactiguard, member of management groups of TeliaSonera and Scania (and corporate finance at SEB).
Board member since: 2023
Committee membership: Chairman of the Audit committee.
Independent in relation to the company, its executive management and the major shareholders of the company.
Total holdings* in BioArctic: 6,500 Class B shares.
Anna-Lena Engwall
Born: 1971
Nationality: Swedish
Other assignments: Global Commercial Vice President Cardiovascular ar Strangeness, based in Cambridge, UK.
Education: B. Sc in Nursing, Karolinska Institutet and DIHM, Marketing and Business.
Experience and prior assignments: More than 25 years of experience in the life science and pharmaceutical industries, with executive roles in commercialization, marketing, and drug and business development, and during her career has held several positions at Shire and Novartis, both in Sweden and internationally.
Board member since: 2024
Committee membership: Audit Committee
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 448 Class B-shares.
Lars Lannfelt
Born: 1949
Other assignments: Founder and board member of Demban AB and LPB Sweden AB.
Education: Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.
Experience and prior assignments: More than 35 years of experience in research into Alzheimer’s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University; member of the Royal Swedish Academy of Sciences. Founder of BioArctic in 2003, Chairman of the Board of BioArctic until 2017 and a number of assignments and roles in the company.
Board member since: 2003
Not independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 8,639,998 Class A-shares through Demban AB. 19,685,052 Class B-shares through Demban AB. Owns 7,000 Class B-shares privately.
Lotta Ljungqvist
Born: 1961
Other assignments: Board member of Genovis AB, NorthXBiologics AB and BioLamina AB.
Education: Degree in biochemistry from KTH Royal Institute of Technology in Stockholm, Sweden. Doctorate in biochemical technology.
Experience and prior assignments: CEO of Testa Center, Cytiva (formerly GE Healthcare Life Sciences). Executive roles as CEO, head of business area, head of research and project manager for biopharma projects at GE Healthcare Life Sciences, Biovitrum and Pharmacia. Board member of several life science companies.
Board member since: 2021
Committee membership: Chairman of the Remuneration Committee.
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 3,159 class B-shares
Linda Nilsson
Born: 1979
Nationality: Swedish
Other assignments: –
Education: Master of Science in Business and Economics from the Stockholm School of Economics.
Experience and prior assignments: More than 20 years of global experience from the international fashion company H&M. She currently holds the position as Head of Product Operations & Development, where she leads approximately 400 employees and is responsible for strategy, governance, and delivery across both product and production. Previously, Linda was Global Managing Director for Womenswear, with full P&L responsibility for a business area generating 40 billion SEK in revenue.
Member since: 2026
Total holdings* in BioArctic: Linda Nilsson is a board member and minority owner in the Gellerfors family’s holding company Ackelsta AB. Ackelsta AB owns 5,759,998 A-shares and 12,143,201 B-shares.
Independent in relation to the company and company management. Not independent in relation to major shareholders in the company.
*Includes own holdings, related-party holdings, holdings in companies and capital insurance accounts as of March, 31, 2026 and also includes any changes thereafter known to the company.
Philip Scheltens
Born: 1957
Nationality: Dutch
Other assignments: Partner and Head of the Dementia Fund in the EQT Life Sciences team.
Education: MD (neurology) and holds a PhD in Medicine from the VU University Amsterdam and is Professor Emeritus of Neurology at the Amsterdam University Medical Center.
Experience and prior assignments: One of the leading international experts in the research, diagnosis and treatment of Alzheimer’s disease. Was appointed as Professor of Cognitive Neurology in 2000 and founded the Alzheimer Center at Amsterdam University Medical Centers in that same year, which he directed until 2022. Has been the (inter)national Principal Investigator (PI) for over 35 studies, including phase 1-3 multicenter clinical trials and supervised >100 PhD theses since 2000. Philip (co)-authored over 1,250 peer-reviewed articles to date. He founded and led the Dutch National Plan against dementia and served as chair of the board until 2021 and was on the advisory panel of the Dutch National Strategy for Dementia until 2025. He acted as chair of the World Dementia council from 2021 – 2025 and is medical advisor to the Race Against Dementia charity and member of the scientific advisory board of the Dementia research Institute.
Member since: 2026
Total holdings* in BioArctic: Philip Scheltens does not own any shares in BioArctic directly or indirectly. However, Philip Scheltens is a partner at EQT and is responsible for EQT’s dementia fund LSP Dementia Fund. LSP Dementia Fund owns 347,500 B-shares.
Independent in relation to the company and management, and to major shareholders in the company.
*Includes own holdings, related-party holdings, holdings in companies and capital insurance accounts as of March, 31, 2026 and also includes any changes thereafter known to the company.
Mikael Smedeby
Born: 1968
Other assignments: Lawyer and partner at Advokatfirman Lindahl. Chairman of the board of Coeli Holding AB (including subsidiaries), Sallengruppen AB (including subsidiaries) and Uppsala Akademiförvaltning. Board member of Sirius Fotboll and Mikael Smedeby Advokat AB.
Education: Master of Laws, Uppsala University, Sweden. Reserve officer training at the Swedish Infantry Officers’ College and the Swedish Infantry Combat School.
Experience and prior assignments: Special experience in corporate law, mergers and acquisitions, financing and licensing. Held executive positions at Advokatfirman Lindahl 2010–2019, including Managing Partner and chairman of the board. Member of the Board of Directors of BioArctic, 2014–2017.
Board member since: 2018
Committee membership: Audit Committee
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 4,422 Class B-shares
*Includes holdings by self, closely associated persons, controlled companies or in capital insurance accounts.